Pfizer and BioNTech begin large-scale trial of coronavirus vaccine in the United States


Drug giant Pfizer and its partner BioNTech have begun an advanced trial of one of their experimental coronavirus vaccines in volunteers in the United States.

The first four participants were dosed Monday at the University of Rochester Medical Center, a spokesman there said. The combined Phase 2/3 trial, which looks for safety, efficacy and optimal dosing of a vaccine or drug, will include up to 30,000 participants.

It was the second advanced trial of a coronavirus vaccine to get under way in the United States Monday. Earlier Monday, Moderna started a Phase 3 trial in the United States of its experimental vaccine. Pfizer’s vaccine is different, but also uses an experimental approach that employs genetic material to stimulate an immune response against a key part of the coronavirus.

Earlier this month, Pfizer and BioNTech released preliminary data showing that one of their vaccines, known only by its experimental name BNT162b1, appeared safe and elicited antibody and T-cell immune responses in a Phase 1/2 trial. US SPREAD GOOD NEWS!

I run this site in my spare time and thoroughly enjoy giving you all positive news!  If you’ve enjoyed the site we’d love for you to help me share the good news far and wide, share us on Reddit, your Facebook or your Twitter and spread a little positivity around.